ReviewJournal of hepatology2021
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
Review in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 137 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101): a Multicenter Cohort Study
Safety and Immunogenicity of COVID-19 Vaccines in Patients With Chronic Liver Disease: A Multi-center Prospective Study
The Fifth Medical Center of Chinese PLA General Hospital
Safety and Immunogenicity of Third Dose SARS-CoV-2 Vaccine Booster in Patients With Liver Diseases Following Two Doses of Inactivated Vaccines (NMCID-CHESS 2201): a Multicenter Cohort Study
Investigation on the Hesitancy of COVID-19 Vaccination Among Liver Transplant Recipients in China
Who cites it
137 citing papers in PubMed, 10 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.Hepatology international · 2024Guideline
- Safety and Efficacy of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases: A Systematic Review and Meta-Analysis.International journal of public health · 2024Pooled it
- HBV/HCV Infection Was Not Significantly Independently Associated with COVID-19 Severity: A Meta-Analysis of Confounding Variables-Adjusted Data.Digestive diseases and sciences · 2023Pooled it
- NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: A meta-analysis.Journal of hepatology · 2023Pooled it
- Cirrhosis is an independent predictor for COVID-19 mortality: A meta-analysis of confounding cofactors-controlled data.Journal of hepatology · 2023Pooled it
- New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review.BMC gastroenterology · 2022Pooled it
- COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.Clinical and molecular hepatology · 2022Pooled it
- Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline.Clinical and molecular hepatology · 2021Guideline
- [Rapid guideline for COVID-19 vaccination in patients with chronic liver diseases, hepatolbiliary malignancy and liver transplant].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Guideline
- The Predictive Value of Myoglobin for COVID-19-Related Adverse Outcomes: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- COVID-19 risk perception, preventive behaviors, vaccination acceptance and hesitancy, and psychosocial status in liver transplant recipients.Frontiers in public health · 2026Article
- COVID-19 Vaccine Perception in Liver Transplant Recipients: Patient-Reported Outcomes and Real-Life Experience from the Bergamo Center.Vaccines · 2025Article
- Article
- Post-COVID-19 Pandemic Sequelae in Liver Diseases.Life (Basel, Switzerland) · 2025Review
- Recommended vaccinations for patients with chronic liver diseases.Clinical and experimental hepatology · 2025Review
- The Impact and Evolution of COVID-19 on Liver Transplant Recipients Throughout the Pandemic "Waves" in a Single Center.Viruses · 2025Observational
- Longitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures.International journal of molecular sciences · 2024Article
- Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study.JHEP reports : innovation in hepatology · 2024Article
- Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer.Tropical medicine and infectious disease · 2024Article
- COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses.GE Portuguese journal of gastroenterology · 2024Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors at 5 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to a recent World Health Organization estimate, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, which originated in China in 2019, has spread globally, infecting nearly 100 million people worldwide by January 2021. Patients with chronic liver diseases (CLD), particularly cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and immunosuppressed individuals after liver transplantation appear to be at increased risk of infections in general, which in turn translates into increased mortality. This is also the case for SARS-CoV-2 infection, where patients with cirrhosis, in particular, are at high risk of a severe COVID-19 course. Therefore, vaccination against various pathogens including SARS-CoV-2, administered as early as possible in patients with CLD, is an important protective measure. However, due to impaired immune responses in these patients, the immediate and long-term protective response through immunisation may be incomplete. The current SARS-CoV-2 pandemic has led to the exceptionally fast development of several vaccine candidates. A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.